Iron is an essential growth factor for the proliferation and differentiation of all living cells in being centrally involved in oxygen transport by hemoglobin and myoglobin, in electron transport during mitochondrial respiration as being a part of complex I and II enzymes or in the regulation of transcription via its role as central component of ribonucelotid reductase (1,2). Moroever, iron plays a critical role in macrophage mediated cytotoxicity by contributing to the production of highly toxic hydroxy radical species needed for host defense (3). In addition, radicals formed by the catalytic action of by iron can modulate the binding affinities of several transcription factors to their target promoter region, such as hypoxia inducible factor -1 or nuclear factor-kB, thus affecting transcription of stress inducible genes (4-6).
Introduction
Iron homeostasis is closely linked to immune function (7) . This is due to the fact that iron availability is a critical determinant for the proliferation and differentiation of immune cells, such as lymphocytes, macrophages or neutrophils, while on the other hand iron exerts regulatory effects on the activity of cell mediated immune function.
In being a central component for all proliferating cclls iron is a dominant regulator of immune cell proliferation and function. Lymphocytes are central regulatory cells of specific immunity. Thus, a sufficient capacity of these cells to proliferate and differentiate is a pre-requisite for normal immune function (8) (9) . Iron has turned out to be involved in these processes, and thus lymphocytes have evoked different mechanisms to acquire iron even under conditions when iron availability is limited. All lymphocytes subsets, which include B-and T-lymphocytes and natural killer (NK) cells, are dependent on transferrin/transferrin receptor (TfR) mediated iron uptake, and a blockade of this pathway leads to diminished proliferation and differentiation of these cells ( 10) . However, the lymphocyte subsets differ in their dependence on transferrin mediated iron uptake. Accordingly, the induction of experimental iron overload in rats resulted in a shift in the ratio between T-helper (CD4+) and T-suppressor/cytotoxic T-cells (CD8+) with a relative expansion of the latter (11) . Moreover, even T-helper (Th) subset responds differently to iron perturbations (12) .
Thus, the interplay between iron and immune function is a critical event deciding about the fate of an infection since microbes have developed sophisticated strategies to acquire iron by membrane bound or soluble siderophores, by transmembrane iron uptake systems which are very similar to that observed in mammals or by endocytotic processes (13, 14) .
Thus, during chronic inflammatory processes disturbanes of body iron homeostasis occur leading to a diversion of iron from the circulation to the iron storage compartments of the reticuloendothelial system (RES). As a consequence typciaf changes in iron homeostasis, clincially reflected by hypoferremia and hyperferritinemia, occur. These changes are hallmarks in the development of anemia of chronic disease (ACD), also known as anemia of inflammation. Anemia of chronic disease is the most frequent anemia The pathophysiological mechanisms underlying ACD include a diminished erythropoiesis, a blunted response to erythropoietin, a decreased erythrocyte half life and most importantly a diversion of iron traffic, which leads to withdrawal of the metal from the sites of erythropoiesis and the circulation to the storage compartment in the reticuloendothelial system. The hypoferremia results from divergent regulatory interactions of various cytokines, their radicals products, cells of the retículo endothelial system and most importantly, by the acute phase protein hepcidin leading to a restricted iron availability for erythroid progenitor cells and thus to anemia. In addition, bacterial toxins and cytokines, such as TNF-a have been proposed to decrease erythrocyte survival and to cause an increased crythro-phagocytosis by splenic macrophages which is compatible with the observation that during inflammatory states an increase of erythrocyte derived iron in splenic macrophages and Kupffer cells takes place (19) . Mainly pro-inflammatory cytokines, such as TNF-a, IFN-yand Type I and Type II interferons, further induce anemia by blocking the proliferation and differentiation of erythroid progenitor cells (BFU-e and CFU-e) (16) . Part of this may be due to direct toxic effects of radicals or ceramide, which cause lipid peroxidation or apoptosis by the cytokines. The suppression of erythropoiesis can be also exerted by invading pathogens as shown for HIV or malaria Plasmodia or tumor cells which by themselves induce the formation of pro-inflammatory cytokines that inhibit erythropoiesis.
Cytokines can also affect the ability of erythroid progenitor cells to respond to erythropoietin and impair the formation of erythropoietin in the kidney as shown for TNF-a and IL-1 (see refs. (15) (16) (17) 20, 21) .
However, pteridines may take part in the pathophysiology of ACD (22) . Neopterin and di-hydroneopterin can modulate radical processes induced by cytokine stimulated macrophages and thus affect the proliferation of neighboring cells, such as erythroid progenitors (23, 24) . In addition, pteridines inhibit the hypoxia inducible production of erythopoietin (25) . Moreover, pteridines can affect iron homeostasis and may thus partly contribute to disturbances of iron metabolism during chronic inflammatory processes.
Modulation of iron homeostasis by pteridines and vice versa
Maintenance of body iron homeostasis is exerted by a tight regulation of iron uptake, iron storage and iron utilization at the organ and cell specific levels. For a long period of time the binding of iron loaded transferrin to cell surface transferrin receptor (TfR) and subsequent endocytosis has been seen as the principal mechanism of iron uptake. After being released from transferrin and passing over from the endosom to the cytoplasm by a currently unidentified mechanism iron is then either utilized upon incorporation into iron containing enzymes or stored following uptake by the iron storage protein ferritin, which consists of 24 subunits formed by light (L) and heavy (H) ferritin peptide chains.
For more then one decade we have learned that the orchestrations of these processes is mainly exerted at the posttranscriptional/translational level by interaction of cytoplasmic proteins, so called iron regulatory proteins (IRP)-l and 2, with RNA stem loop structures, iron responsive elements (IRE). IREs have been identified within the 5' untranslated regions of the mRNAs coding for the central proteins for iron storage (Hchain and L-chain ferritin) and iron consumption (erythroid amino levulinc acid synthase, e-ALAS, the key enzyme in heme-biosynthesis), while the mRNA coding for the major iron uptake protein, TfR, bears five IREs within its 3' untranslated region (1,2). Iron deficiency in cells stimulates the binding affinity of IRPs to IREs thus resulting in blocking of ferritin and e-ALAS expression by affecting the formation of the translation initiation complex. Conversely, binding of IRPs to the IREs within the 3' untranslated region of TfR mRNA results in increased expression of this protein by prolonging TfR mRNA half life. In contrast, iron overload in cells reduces the target affinity of IRPs to IREs which then causes de-repression of ferritin and e-ALAS translation while TfR mRNA is degraded which in turn results in limitation of TfR mediated iron uptake while iron storage (ferritin synthesis) or iron consumption (heme synthesis) is induced.
The recent identification of transmembrane iron transporters has widened our knowledge of cellular iron traffic. The divalent metal transporter-1 (DMT-1 ) is a transmembrane protein which is centrally involved in the absorption of ferrous iron from the duodenum and the intracellular delivery of iron to erythroid progenitor cells (26) . As a collaborating counterpart to DMT-1 the protein ferroportin (also named IREG-1 or MTP-1) is able to export iron across the basolateral membrane of enterocytes and to donate the metal after being oxidized by a membrane bound ferroxidase to the circulation (27) . Changes in iron homeostasis such as iron deficiency or iron overload are paralleled by marked changes of DMT-1 and ferroportin expression while mutations of DMT-1 and/or ferroportin are associated with microcytic anemia or iron overload, respectively. Both, DMT-1 and ferroportin contain a single IRE within the untranslated regions of their m RNA, however, their functionality in order to induce posttranscriptional/translational regulation of DMT-1 or ferroportin m RNA expression is still under investigation (28, 29) . The expression of DMT-1 and ferroportin are affected by cytokines as are iron uptake and release pathways in macrophages, thus resulting in increased iron accumulation under chronic inflammatory processes (30) .
A possible link of pteridines to iron homeostasis has been first described by the observation that pteridines may affcct the affinity of iron for transferrin (31) . More importantly, the observation of an inverse correlation between neopterin levels and hemoglobin concentrations in patients with ACD suggested that pteridines may affect iron homeostasis.
However, at first the opposite turned out to be true, namely, that iron regulated the cytokine inducible formation of pteridines.
Iron loading of macrophages results in an inhibition of IFN-γ mediated pathways towards these cells. Thus, such cells presented with a reduced IFN-γ inducible formation of neopterin and TNF-a, reduced expressions of MHC class II antigens and ICAM-1, and finally impaired tryptophan degradation via IFN-γ mediated induction of indole-amine-2,3-dioxygenase (32-34). The mechanism underlying iron mediated regulation of IFN-γ have not been fully elucidated so far but most likely involve an interaction of iron with cytokine mediated signal transduction processes although STAT-1 phosphorylation ,as a central effector pathway for IFN-γ, is not affected by iron overload (33) .
As a consequence of this iron loaded macrophages loose their ability to kill intracellular pathogens by IFN-γ mediated pathways, such as Legionella, Listeria, Ehrlichia, Candida and also viruses, in vitro and in vivo (35, 36) . Part of this can be attributed to the reduced formation of nitric oxide (NO) in the presence of iron. This is of importance since NO is an essential effector molecule of macrophages to fight infectious pathogens and tumor cells (37) . Iron blocks the transcription of inducible NO-synthase (iNOS or NOSII), the enzyme being responsible for cytokine inducible high-output formation of NO by hepatocytes or macrophages, and by inhibiting the binding affinity of NF-IL6 and of hypoxia inducible factor 1 to the iNOS promoter iron impairs iNOS transcription and reduces its inducibility by cytokines (5, 6, 38) . The clinical relevance of this observation has been underlined by several studies, e.g. with PI. falciparum malaria. A placebo controlled, double blinded randomized study demonstrated that iron restriction upon therapeutic application of the iron chelator, desferrioxamine, in addition to a standard anti-malarial treatment resulted in an improved clinical course as reflected by a shorter duration of coma and fever and an increased clearance of Plasmodia from the circulation (39) . Children receiving desferrioxamine had higher levels of Th-1 cytokines, neopterin and NO while serum concentration of Th-2 cytokines (IL-4) tended to be lower (40) which indicated that withdrawal of iron increases Th-1 mediated immune function also in vivo (41) and that the effects of desferrioxamine can not be referred to sole iron restriction to PI. falciparum (41) .
Several studies investigated the effects of iron homeostasis on the course or incidence of infections and cancer (42) . Interestingly, in one study iron deficient children had a reduced incidence of infection as compared to children with a balanced iron status (42, 43) . Iron deficiency was associated with a higher percentage of CD8+ cells producing IL-6, a more pronounced expression of T-cell activation markers on lymphocytes and an increased formation of IFN-γ as compared to children with a normal iron status (43) .
Such observations were traced back to the fact that limitation of iron availability to invading pathogens and tumor cells limits their growth by reducing the amount of this essential nutrient needed for their proliferation (42) while at the same time iron deficiency may strengthen T-cell mediated immune function (36) .
The modulatory effects of iron towards IFN-γ activity affects the Th-l/Th-2 balance with Th-1 effector function being weakened while Th-2 mediated cytokine production and function, such as IL-4 activity, being increased, a condition which is a rather unfavorable condition in case of a tumor disease or an infection (40, 44) .
Thus, iron availability strongly affects cytokine inducible formation of pteridines by inhibiting IFN-γ mediated immune effector pathways. In addition, in being a critical catalyser for radical formation iron also affects pteridine stability, as shown for tetrahydobiopterin (BH 4 ), thus influencing enzymatic processes which are under the control of BH 4 , such as neurotransmitter synthesis or constitutive NO formation (45) .
As iron affects pteridine synthesis pteridines can modulate cellular iron regulation via iron responsive elements. This can be traced back to the co-factor role of BH 4 for nitric oxide formation (45) . By stimulating the formation of NO via increasing the cellular avail-
